Clinical Trial

A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-19.
Status change: Active, Not Recruiting → Completed 2026-03-09
Trial Details
NCT Number NCT07428525
Lead Sponsor Amgen
Conditions Hepatic Impairment
Enrollment 36 participants
Start Date 2025-03-14
Primary Completion 2026-02-26 (estimated)
Study Completion 2026-02-26 (estimated)
Updated on ClinicalTrials.gov 2026-03-11